Literature DB >> 3014351

Analysis of human T-lymphotrophic virus sequences in multiple sclerosis tissue.

S L Hauser, C Aubert, J S Burks, C Kerr, O Lyon-Caen, G de The, M Brahic.   

Abstract

Several observations suggest that retroviral infection is involved in the pathogenesis of the human demyelinating disease multiple sclerosis (MS). First, lymphadenopathy-associated virus/human T-lymphotropic virus type III (LAV/HTLV-III), the agent of acquired immune deficiency syndrome (AIDS), has been shown to be neurotropic in man. Second, the genetic organization of the lentivirus visna, which causes a chronic demyelinating disease of sheep, closely resembles that of LAV/HTLV-III. Recently, Koprowski and colleagues reported that MS is associated both with raised levels of circulating antibodies to HTLV-I and with the presence of HTLV-I-specific RNA within cell lines derived from the cerebrospinal fluid (CSF). Here we report that no HTLV-I-like or LAV/HTLV-III-like sequences can be detected, by in situ hybridization, in central nervous system (CNS) tissues from MS patients, and that nonspecific HTLV-I-like signal in peripheral blood mononuclear cells or in CSF cell lines is characteristic of MS. Furthermore, enzyme-linked immunosorbent assay (ELISA) analysis of circulating and CSF antibodies for HTLV-I reactivity fails to distinguish between MS and control groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014351     DOI: 10.1038/322176a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

1.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

2.  Multiple sclerosis and human T-cell lymphotropic retroviruses: negative serological results in 135 German patients.

Authors:  J Schneider; B Kitze; G Hunsmann; I Wendler; L Kappos
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

3.  Human T-cell lymphotrophic viruses in patients with multiple sclerosis.

Authors:  R J Swingler; P J Hughes; J A Munro; D A Compston
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

4.  Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis.

Authors:  Robert P Lisak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-09       Impact factor: 11.205

5.  Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification.

Authors:  S J Greenberg; G D Ehrlich; M A Abbott; B J Hurwitz; T A Waldmann; B J Poiesz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

6.  Failure to find HTLV I and HIV I serum antibodies in MS patients.

Authors:  R Capra; F Mattioli; N Manca; G Scura
Journal:  Ital J Neurol Sci       Date:  1988-06

7.  Search for retroviral sequences in peripheral blood mononuclear cells and brain tissue of multiple sclerosis patients.

Authors:  R Jocher; A Rethwilm; L Kappos; V ter Meulen
Journal:  J Neurol       Date:  1990-10       Impact factor: 4.849

8.  Human spumaretrovirus antibody reactivity in multiple sclerosis.

Authors:  J Lycke; B Svennerholm; A Svenningsson; W Muranyi; R M Flügel; O Andersen
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

9.  Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency.

Authors:  Ricardo F Frausto; Stephen J Crocker; Boreth Eam; Jason K Whitmire; J Lindsay Whitton
Journal:  J Neuroimmunol       Date:  2007-10-26       Impact factor: 3.478

10.  A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients.

Authors:  M Pazhouhandeh; M-A Sahraian; S D Siadat; A Fateh; F Vaziri; F Tabrizi; F Ajorloo; A K Arshadi; E Fatemi; S Piri Gavgani; F Mahboudi; F Rahimi Jamnani
Journal:  Clin Exp Immunol       Date:  2018-01-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.